ReviewPharmacotherapy2013
Abacavir pharmacogenetics--from initial reports to standard of care.
Review in Pharmacotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 64 citations in OpenAlex.
- Gaps in guideline adherence: evaluating HLA-B*57:01 screening for abacavir sensitivity and the implementation of evidence-based HIV care.Clinical biochemistry · 2025Article
- Review
- Precision Medicine-Are We There Yet? A Narrative Review of Precision Medicine's Applicability in Primary Care.Journal of personalized medicine · 2024Review
- Frequency of Human Leukocyte Antigen-B*57:01 Allele Carriers in People Living with HIV/AIDS in Türkiye.Current HIV research · 2024Article
- Predictive Value ofGenes · 2023Article
- Repurposed Drugs in Gastric Cancer.Molecules (Basel, Switzerland) · 2022Review
- Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report.Journal of medical case reports · 2022Article
- Prescribing for patients taking antiretroviral therapy.Australian prescriber · 2022Review
- Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Article
- Unravelling the Proteomics of HLA-B*57:01Journal of personalized medicine · 2022Article
- The Immunogenetics of Cutaneous Drug Reactions.Advances in experimental medicine and biology · 2022Article
- Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study.The pharmacogenomics journal · 2021Article
- Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait.PloS one · 2018Article
- Development of peptide inhibitors of HIV transmission.Bioactive materials · 2016Review
- Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient.BMJ case reports · 2015Article
- Global implementation of genomic medicine: We are not alone.Science translational medicine · 2015Review
- Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.PloS one · 2015Article
- Genes, the environment and personalized medicine: We need to harness both environmental and genetic data to maximize personal and population health.EMBO reports · 2014Article
- Community pharmacists' attitudes towards clinical utility and ethical implications of pharmacogenetic testing.Personalized medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Abacavir is a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus infection as part of a multidrug, highly active antiretroviral therapy regimen. Despite its efficacy, approximately 5% of individuals who receive abacavir develop an immune-mediated hypersensitivity reaction (HSR) that warrants immediate discontinuation of abacavir and switching to an alternative antiretroviral regimen. Abacavir HSR is associated with individuals who carry the *57:01 variant in the human leukocyte antigen B (HLA-B) gene. There is a large volume of evidence to show that those who carry HLA-B*57:01 are at significantly increased risk of developing HSR and should not receive abacavir. Pharmacogenetic screening to ensure individuals who carry HLA-B*57:01 do not receive abacavir can reduce the incidence of HSR and is now considered the standard of care before prescribing abacavir. Genetic testing to prevent abacavir HSR is currently one of the best examples of integrating pharmacogenetic testing into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.